Npc2 Protein — Niemann Pick C2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute |
Value |
| Protein Name |
NPC2 (Niemann-Pick C2 Protein) |
| Gene |
NPC2 |
| UniProt ID |
O15148 |
| Molecular Weight |
~17 kDa (151 amino acids) |
| Subcellular Localization |
Lysosome, late endosome |
| Protein Family |
NPC2 family |
| Structure |
Beta-sandwich fold |
NPC2 is a small soluble lysosomal protein (151 amino acids) with a compact beta-sandwich fold. The protein binds a single molecule of unesterified cholesterol in its hydrophobic cavity. Key structural features:
- N-terminal signal sequence: Targets protein to lysosome via mannose-6-phosphate independent pathway
- Beta-sandwich core: Forms cholesterol-binding pocket
- Hydrophobic cavity: Single cholesterol molecule binding site
- Disulfide bonds: Two conserved cysteine residues stabilize structure
- Methylation sites: Affects protein stability and function
The cholesterol-binding pocket:
- Binds unesterified cholesterol (not cholesteryl esters)
- Recognizes the 3-beta-hydroxy group
- Hydrophobic interactions stabilize binding
- May also bind oxysterols
NPC2 plays a critical role in cholesterol export from lysosomes:
- Binds cholesterol released from LDL degradation
- Transfers cholesterol to NPC1 protein
- Works in concert with NPC1 to export cholesterol to the ER and plasma membrane
- LDL uptake: Extracellular LDL enters via receptor-mediated endocytosis
- Lysosomal delivery: LDL delivered to late endosomes/lysosomes
- Cholesterol release: Acidic lipases release cholesterol from LDL
- NPC2 binding: NPC2 captures free cholesterol
- NPC1 transfer: NPC2 hands cholesterol to NPC1
- Membrane export: NPC1 mediates cholesterol efflux
- Cellular distribution: Cholesterol reaches ER, Golgi, plasma membrane
NPC2 mutations cause approximately 10% of NPC cases:
| Mutation Type |
Effect |
Phenotype |
| Missense |
Partial function |
Adult-onset NPC |
| Nonsense |
Null |
Severe childhood NPC |
| Frameshift |
No protein |
Severe infantile NPC |
Clinical Features:
- Lysosomal cholesterol accumulation (all cell types)
- Hepatomegaly, splenomegaly
- Neurological deterioration
- Cerebellar ataxia, dystonia, seizures
- Vertical supranuclear gaze palsy
- Premature death (usually by age 20)
Similar mechanisms to NPC1:
- Cholesterol dysregulation affects neuronal function
- Membrane composition changes
- Synaptic dysfunction
- May modify other neurodegenerative diseases:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
| Treatment |
Mechanism |
Status |
| Miglustat (Zavesca) |
Substrate reduction |
FDA approved for NPC |
| Arimoclomol |
HSP90 inducer |
FDA approved for NPC |
| Approach |
Description |
Stage |
| Cyclodextrin |
Cholesterol extraction |
Clinical trials |
| Gene therapy (AAV-NPC2) |
Viral delivery of functional NPC2 |
Preclinical |
| Small molecule correctors |
Improve NPC2 folding |
Research |
| Enzyme replacement |
Not applicable |
N/A |
NPC2 interacts with:
- NPC1: Direct protein-protein interaction for cholesterol handoff
- Lysosomal enzymes: Acid lipase
- Membrane proteins: Facilitates cholesterol transfer
NPC2 is expressed in:
- All tissues (ubiquitous)
- Highest in liver, spleen, brain
- Localized to lysosomes in all cell types
In brain:
- Friedland N, et al. (2003). Structure of a cholesterol-binding protein NPC2. Proc Natl Acad Sci.[1]
- Vanier MT, et al. (2015). Niemann-Pick disease type C. Nat Rev Dis Primers.[2]
- Storch J, et al. (2009). Lipid transfer proteins in NPC disease. J Lipid Res.[3]
- Patton-Vogt J, et al. (2018). Cyclodextrin therapy for NPC. Mol Genet Metab.[4]
- Kumar N, et al. (2021). Gene therapy for NPC. Nat Commun.[5]
The NPC2 protein (151 amino acids, ~15 kDa) has several key features:
- Signal peptide (1-19): Targets to secretory pathway
- Mature protein (20-151): Functional lysosomal protein
- Hydrophobic pocket (60-140): Binds cholesterol and other lipids
- Disulfide bond (Cys47-Cys73): Structural stability
NPC2 binds cholesterol with high affinity:
- Cholesterol enters lysosome via endocytosis
- NPC2 captures cholesterol in lysosomal lumen
- Conformational change facilitates NPC1 transfer
- NPC1 mediates cholesterol export to cytosol
NPC2 can bind multiple lipids:
- Cholesterol (primary)
- 7-ketocholesterol (oxysterol)
- Phytosphingosine
- Glycerophospholipids
- Bile acids
NPC2 may serve as a biomarker:
- Elevated in some lysosomal storage disorders
- Cerebrospinal fluid levels in NPC disease
- Correlates with disease severity
- Newborn screening for NPC
- Prenatal diagnosis
- Carrier detection
- Miglustat efficacy
- Disease progression
- Treatment response
The study of Npc2 Protein — Niemann Pick C2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Friedland N, et al. Structure of a cholesterol-binding protein NPC2. Proc Natl Acad Sci. 2003;100(5):2512-2517.
[2] Vanier MT, et al. Niemann-Pick disease type C. Nat Rev Dis Primers. 2015;1:15021.
[3] Storch J, et al. Lipid transfer proteins in NPC disease. J Lipid Res. 2009;50(9):1727-1734.
[4] Patton-Vogt J, et al. Cyclodextrin therapy for NPC. Mol Genet Metab. 2018;123(2):S95.
[5] Kumar N, et al. Gene therapy for NPC. Nat Commun. 2021;12(1):3628.